We first tested if CYP2C19 metabolic phenotypes are associated with antidepressant response, side effects, and adverse events—as inferred from treatment discontinuation or switching to another antidepressants—in bipolar depression. The gene discussed is CYP2C19; the disease is bipolar disorder.